StrongBox Wealth LLC Purchases 56 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

StrongBox Wealth LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 12.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 517 shares of the medical research company’s stock after purchasing an additional 56 shares during the period. StrongBox Wealth LLC’s holdings in Thermo Fisher Scientific were worth $281,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Mystic Asset Management Inc. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Advanced Research Investment Solutions LLC lifted its stake in Thermo Fisher Scientific by 213.3% in the first quarter. Advanced Research Investment Solutions LLC now owns 47 shares of the medical research company’s stock worth $28,000 after purchasing an additional 32 shares during the last quarter. Adirondack Trust Co. bought a new stake in Thermo Fisher Scientific in the second quarter worth about $34,000. Oliver Lagore Vanvalin Investment Group bought a new stake in Thermo Fisher Scientific in the first quarter worth about $38,000. Finally, Lloyd Advisory Services LLC. lifted its stake in Thermo Fisher Scientific by 294.1% in the first quarter. Lloyd Advisory Services LLC. now owns 67 shares of the medical research company’s stock worth $40,000 after purchasing an additional 50 shares during the last quarter. 86.50% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $2.85 during trading hours on Friday, hitting $517.44. 17,492 shares of the company’s stock traded hands, compared to its average volume of 1,076,331. The firm’s 50-day moving average is $567.60 and its 200-day moving average is $558.21. Thermo Fisher Scientific Inc. has a 52-week low of $497.83 and a 52-week high of $672.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.65 and a quick ratio of 1.13. The company has a market capitalization of $202.73 billion, a PE ratio of 27.69, a PEG ratio of 1.64 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last issued its quarterly earnings data on Thursday, July 28th. The medical research company reported $5.51 EPS for the quarter, topping the consensus estimate of $4.92 by $0.59. The firm had revenue of $10.97 billion for the quarter, compared to analyst estimates of $9.95 billion. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. The business’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same period in the prior year, the business posted $5.60 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 22.92 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Shareholders of record on Thursday, September 15th will be given a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.23%. The ex-dividend date of this dividend is Wednesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.39%.

Analysts Set New Price Targets

Several research firms have recently weighed in on TMO. Credit Suisse Group assumed coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, August 24th. They set a “neutral” rating and a $675.00 price target for the company. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $670.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, July 29th. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $685.00 to $595.00 and set an “overweight” rating for the company in a research note on Monday, September 12th. Finally, SVB Leerink boosted their target price on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a research report on Friday, July 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $656.56.

Insider Activity at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 12,300 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $603.48, for a total value of $7,422,804.00. Following the transaction, the chief financial officer now directly owns 43,944 shares of the company’s stock, valued at approximately $26,519,325.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 12,300 shares of the firm’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $603.48, for a total transaction of $7,422,804.00. Following the transaction, the chief financial officer now directly owns 43,944 shares of the company’s stock, valued at approximately $26,519,325.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 7,283 shares of the firm’s stock in a transaction on Monday, August 8th. The stock was sold at an average price of $590.80, for a total transaction of $4,302,796.40. Following the transaction, the senior vice president now directly owns 12,398 shares in the company, valued at $7,324,738.40. The disclosure for this sale can be found here. Insiders have sold 55,397 shares of company stock valued at $33,012,754 in the last ninety days. Insiders own 0.43% of the company’s stock.

Thermo Fisher Scientific Company Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.